/
BCAB
$3.48+$0.07 (+2.07%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$5.6M
2M shares
52-week range
$3.12 – $71.50
1% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Change$-1996.55
BioAtla, Inc. Common Stock
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.
www.bioatla.com- Employees
- 41
- IPO / List date
- Dec 16, 2020
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds BCAB.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in BCAB as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-04-06 | 1-for-50reverse |
Recent trades on TradeandTell
No one on the platform has traded BCAB yet.
